Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know

Isabelle Opitz; Raphael Bueno; Eric Lim; Harvey Pass; Ugo Pastorino; Mattia Boeri; Gaetano Rocco

doi:10.1093/ejcts/ezu048

Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know

Isabelle Opitz, Raphael Bueno, Eric Lim, Harvey Pass, Ugo Pastorino, Mattia Boeri, Gaetano Rocco

Research output: Contribution to journal › Article › peer-review

Abstract

Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.

Original language	English
Article number	ezu048
Pages (from-to)	602-606
Number of pages	5
Journal	European Journal of Cardio-thoracic Surgery
Volume	46
Issue number	4
DOIs	https://doi.org/10.1093/ejcts/ezu048
Publication status	Published - Oct 1 2014

Keywords

Biomarker
Genomic sequencing
Lung cancer
Malignant pleural mesothelioma
microRNAs

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Surgery
Pulmonary and Respiratory Medicine

Access to Document

10.1093/ejcts/ezu048

Cite this

@article{9ec9d292439743debfe56fa97435ebdf,

title = "Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know",

abstract = "Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.",

keywords = "Biomarker, Genomic sequencing, Lung cancer, Malignant pleural mesothelioma, microRNAs",

author = "Isabelle Opitz and Raphael Bueno and Eric Lim and Harvey Pass and Ugo Pastorino and Mattia Boeri and Gaetano Rocco",

year = "2014",

month = oct,

day = "1",

doi = "10.1093/ejcts/ezu048",

language = "English",

volume = "46",

pages = "602--606",

journal = "European Journal of Cardio-thoracic Surgery",

issn = "1010-7940",

publisher = "European Association for Cardio-Thoracic Surgery",

number = "4",

}

TY - JOUR

T1 - Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer

T2 - What thoracic surgeons should know

AU - Opitz, Isabelle

AU - Bueno, Raphael

AU - Lim, Eric

AU - Pass, Harvey

AU - Pastorino, Ugo

AU - Boeri, Mattia

AU - Rocco, Gaetano

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.

AB - Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.

KW - Biomarker

KW - Genomic sequencing

KW - Lung cancer

KW - Malignant pleural mesothelioma

KW - microRNAs

UR - http://www.scopus.com/inward/record.url?scp=84928190118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928190118&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezu048

DO - 10.1093/ejcts/ezu048

M3 - Article

C2 - 24623168

AN - SCOPUS:84928190118

SN - 1010-7940

VL - 46

SP - 602

EP - 606

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

IS - 4

M1 - ezu048

ER -

Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: What thoracic surgeons should know

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this